API Holdings

What API Holdings does

API Holdings is India's largest digital healthcare platform by GMV, operating an integrated, end-to-end ecosystem that serves consumers, pharmaceutical companies, wholesalers, pharmacies, hospitals, doctors, clinics, and diagnostic labs. Headquartered in Navi Mumbai with 5,001-10,000 employees, the company was formally consolidated in August 2020 from businesses the founding team had built since 2012 (originally as Dialhealth) and currently controls six operating brands: PharmEasy, Ascent, Retailio, Thyrocare, Docon, and Aknamed. The group commands approximately 35% of India's e-pharmacy market and reports ₹6,869 Cr in consolidated FY26 revenue, up 14.3% year-over-year, alongside its first-ever positive group EBITDA of ₹62.5 Cr.

The platform is built on a custom microservices architecture with AI-driven automated observability (IBM Instana) deployed across PharmEasy, Thyrocare, and Retailio, achieving a 30% reduction in Mean Time to Resolution. PharmEasy operates as India's largest online pharmacy marketplace using an asset-light model partnering with local pharmacies for last-mile fulfillment. Ascent/Retailio form the B2B distribution backbone, serving over 100,000 pharmacies across 20 Indian states through a proprietary warehouse management system with internal sourcing increased to 100% from a previous 20-30%. Thyrocare is India's largest diagnostics provider by test volumes, with its franchise network expanded from 2,700 to nearly 10,000 locations, while Docon provides EMR and practice management software and Aknamed serves as a tech-enabled supplier of specialty medicines, surgical devices, and medical products to hospitals.

Revenue is generated through five streams: marketplace commissions of 8-15% on B2C medicine sales (PharmEasy), transaction fees on B2B pharma distribution (Ascent/Retailio), diagnostic test margins of 20-25% with 33.8% standalone EBITDA at Thyrocare, teleconsultation and EMR fees (Docon), and advertising plus loyalty programs. Under new Managing Director and CEO Rahul Guha (appointed August 2025), the company has shifted from an expansion-first to a profit-first execution model, reducing debt from approximately ₹1,800 Cr to ₹1,050 Cr and cutting interest costs from 20%+ to 11-12%, with a stated target of a public listing within approximately twelve months.

Name

API Holdings

Legal name

API Holdings Limited

Website

https://apiholdings.in

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

API Holdings is India's largest integrated digital healthcare platform, operating online pharmacy (PharmEasy, ~35% e-pharmacy share), B2B pharma distribution (Retailio/Ascent, 100,000+ pharmacies), diagnostics (Thyrocare), EMR/teleconsultation (Docon), and hospital supplies (Aknamed) for consumers, pharmacies, doctors, hospitals, and pharma companies.

Ownership category

akta.pro rank

Product category

Digital Healthcare Platform

NAICS

Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292), Professional, Scientific, and Technical Services (541)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Health & Pharmacy Omnichannel (CRAFAEAK)

akta.pro secondary industries

Medical, Dental & Lab Supply Marketplaces (CRAFAHAG), Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK)

Keywords

• Online pharmacy
• Healthcare distribution
• Diagnostic services
• Pharma B2B platform
• Teleconsultation services

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Medicine Commissions (B2C Pharmacy): PharmEasy operates as an online pharmacy marketplace earning commissions of 8-15% on medicine sales. The platform connects consumers with partner pharmacies for home delivery of pharmaceutical products.
2. Diagnostic Margins (Thyrocare): Thyrocare diagnostics business generates margins of 20-25%, operating as India's largest diagnostic test provider by volumes. Standalone EBITDA margin of 33.8% in FY26.
3. B2B Distribution (Ascent/Retailio): Ascent and Retailio serve over 100,000 pharmacies across 20 states in India, distributing pharma products through proprietary warehouse management systems. Internal sourcing from Ascent increased to 100% from 20-30% previously.
4. Doctor Consultations & Telemedicine: Docon provides EMR and clinic management services along with teleconsultation offerings for doctors, clinics and patients, generating revenue from consultation fees.
5. Advertising & Loyalty Programs: Additional revenue streams from advertising placements and loyalty programs within the PharmEasy platform.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels3 records

Core offering

API Holdings operates India's largest digital healthcare platform, providing an integrated, end-to-end ecosystem that serves every stakeholder in the healthcare value chain. Through its portfolio of brands — PharmEasy (B2C online pharmacy marketplace), Ascent/Retailio (B2B pharma distribution to 100,000+ pharmacies), Thyrocare (diagnostics), Docon (EMR and teleconsultation), and Aknamed (hospital supplies procurement) — the company delivers on-demand medicine delivery, wholesale pharmaceutical distribution, diagnostic testing, and clinic/hospital technology solutions to consumers, pharmacies, doctors, and hospitals across India.

Product overview

API Holdings operates a platform-plus-modules architecture consisting of India's largest digital healthcare ecosystem. The portfolio includes PharmEasy (B2C online pharmacy marketplace), Retailio (B2B pharma platform connecting pharmacies with wholesalers), Ascent (B2B distribution backbone with warehouse management), Thyrocare (diagnostics), Docon (EMR and teleconsultation), and Aknamed (hospital supplies procurement). These products form an integrated end-to-end digital healthcare platform serving consumers, pharmaceutical companies, wholesalers, pharmacies, hospitals, doctors, clinics, and diagnostic labs through interconnected technology and fulfilment capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• PharmEasy: India's largest online pharmacy marketplace, operating as a hybrid marketplace connecting patients, pharmacies, diagnostic labs, and healthcare providers through B2C services
• Ascent

Products and services

• PharmEasy India's largest online pharmacy marketplace, operating as a hybrid marketplace that connects patients with partner pharmacies for on-demand home delivery of pharmaceutical products, teleconsultation access, and diagnostic bookings through an asset-light model with ~35% e-pharmacy market share.
• Retailio One of India's largest pharma B2B platforms connecting pharmacies with wholesalers, enabling lower stock-outs, efficient inventory and expiry management, and reduced manual re-ordering cycles for retailers through data-driven demand forecasting.
• Ascent B2B pharmaceutical wholesale distribution business serving over 100,000 pharmacies across 20 states in India through a proprietary warehouse management system; one of India's largest pharmaceutical wholesalers by GMV by December 2018.
• Thyrocare India's largest diagnostics test provider by volumes, offering routine and specialized diagnostics including genomics and histopathology through a franchise network expanded from 2,700 to nearly 10,000 locations, with 33.8% standalone EBITDA margin in FY26.
• Docon EMR and practice management software for clinics and doctors, providing teleconsultation offerings for doctors, clinics, and patients alongside clinic workflow digitization.
• Aknamed Tech-enabled procurement platform and one of the largest suppliers of specialty medicines, pharmaceutical drugs, surgical, and medical devices to doctors and hospitals in India.

Quantifiable outcome

• Revenue of ₹6,869 Cr in FY26, up 14.3% from FY25
• +5 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• IBMcoreTechnology or IntegrationIBM deployed its Instana AI-driven automated observability platform across API Holdings' microservices architecture spanning three major business units. The implementation delivered a 30% reduction in Mean Time to Resolution, improved developer productivity, and created a scalable foundation for faster time-to-market of new services.
• SOCARminorStrategic or Co-development PartnerSOCAR, Azerbaijan's state oil company, completed its acquisition of a 99.82% stake in Italiana Petroli from API Holding following European Commission approval. Italiana Petroli operates around 4,500 fuel stations and refining assets with capacity of approximately 10 million tonnes per year.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Tata 1mg: Tata 1mg is one of India's largest online pharmacy and digital health platforms offering medicine delivery, diagnostics booking, and teleconsultation — directly competing with PharmEasy across the same B2C categories and serving an overlapping Indian consumer base.
• Reliance Retail (Netmeds / JioMart Health): Reliance's Netmeds and JioMart Health platforms compete directly with PharmEasy in online pharmacy and are backed by the Reliance ecosystem's deep capital and distribution, making them the most consequential direct competitor in India.
• MedPlus: MedPlus is one of India's largest pharmacy retail chains with an integrated online platform, competing with PharmEasy on both offline pharmacy footprint and online medicine delivery in overlapping Indian markets.
• Practo: Practo is an Indian digital healthcare platform offering online doctor consultations, appointment booking, and EMR solutions — directly competing with API Holdings' Docon business in the teleconsultation and practice-management space.

Broad incumbents

• Apollo Pharmacy / Apollo 24|7: Apollo operates India's largest offline pharmacy chain and its Apollo 24|7 digital platform spanning pharmacy, diagnostics, and teleconsultation; broader portfolio (hospitals, clinics) makes it a broad incumbent that overlaps with API Holdings' omnichannel healthcare ambitions.
• Dr. Lal PathLabs: Dr. Lal PathLabs is one of India's largest diagnostic chains by network and revenue; as a broad incumbent in the diagnostics category where Thyrocare competes, it represents a credible competitive comparison on scale, brand, and pan-India footprint.
• Metropolis Healthcare: Metropolis Healthcare is a leading pan-India diagnostic chain offering pathology and preventive health testing — comparable to Thyrocare in diagnostics services, with comparable B2B collection-center models serving hospitals and physicians.

Emerging players

• Amazon Pharmacy (India): Amazon Pharmacy in India offers online medicine delivery with Prime-linked logistics and aggressive pricing; its emerging but rapidly scaling presence threatens PharmEasy's B2C pharmacy market share with effectively unlimited capital backing.
• Flipkart Health+: Flipkart Health+ is the Walmart-backed e-pharmacy venture operating in India; an emerging player with strong e-commerce logistics but still building scale, it represents a future threat to PharmEasy's consumer pharmacy share.

Regional players

• SastaSundar Healthbuddy: SastaSundar is an Indian digital health platform combining pharmacy, diagnostics, and teleconsultation primarily focused on eastern India; it serves as a comparable regional digital-health ecosystem player to API Holdings with similar end-to-end value chain coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ApiHoldings
• LinkedInlinkedin.com/company/api-holdings

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries7 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about API Holdings